/

Società

Ge

Non verificato

Genascence Corporation

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

2 comunicati stampa

Guarda tutti i comunicati

16/07/2025

Igiene alimentare

Salute

Biotecnologia

Farmaceutica

Medicina - Varie

Industria

Genascence Announces U.S. Food and Drug Administration Grants Regenerative Medicine Advanced Therapy Designation to GNSC-001 for Knee Osteoarthritis (OA)

Fonte

Genascence Corporation

Emittente

1.00

0

12/05/2025

Eventi

Industria

Biotecnologia

Salute

Farmaceutica

Medicina - Varie

Genascence Phase 1b DONATELLO Trial Evaluating Potential First-in-Class Gene Therapy for Knee Osteoarthritis (OA) Meets Primary Endpoint Showing GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms

Fonte

Genascence Corporation

Emittente

1.00

0

Seguaci

0

Compatibilità

0